Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Int J Surg. 2014;12 Suppl 1:S52-6. doi: 10.1016/j.ijsu.2014.05.054. Epub 2014 May 23.

Emerging molecular markers for the prognosis of differentiated thyroid cancer patients.

Author information

  • 1Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
  • 2Department of Surgical Sciences, "Sapienza" University of Rome, Italy.
  • 3Department of Surgery "Pietro Valdoni", "Sapienza" University of Rome, Italy.
  • 4Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy. Electronic address: salvatore.ulisse@uniroma1.it.


Epithelial thyroid cancers are represented by the differentiated papillary and follicular thyroid carcinomas which, following dedifferentiation, are thought to give rise to the highly aggressive and incurable anaplastic thyroid carcinomas. Although derived from the same cell type, the different thyroid tumors show specific histological features, biological behavior and degree of differentiation as a consequence of different genetic alterations. Over the last few years, our knowledge regarding the molecular alterations underlying thyroid cell malignant transformation and cancer progression has considerably increased; however, the prognosis of differentiated thyroid cancer patients still relies on high-risk clinic-pathological variables. In particular, the actual staging systems provides only a rough prediction for cancer mortality and risk of recurrences, including in each risk group patients with highly different tumor-specific progression, disease-free interval and survival time. In order to improve DTC patient's risk stratification, both the European and the American Thyroid Associations proposed practical guidelines to integrate the actual staging systems with additional clinical features such as the tumor histological variant, the results of post-ablative whole body scan and the serum thyroglobulin levels. Despite that, patients within the same risk group still show a very heterogeneous behavior in terms of disease-free interval. As a consequence, the identification of new prognostic molecular biomarkers able to testify tumor aggressiveness is highly required. Here we'll review recently characterized new molecular markers potentially able to ameliorate the prognosis in DTC patients.

Copyright © 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.


BRAF; Estrogen receptor; Prognosis; TNM; Thyroid cancer; Urokinase plasminogen activating system; miRNA

[PubMed - in process]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk